• 1
    Sellal F. [Transient amnesia in the elderly]. Psychol Neuropsychiatr Vieil 2006; 4: 318.
  • 2
    Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 4559.
  • 3
    Favreliere S, Lafay-Chebassier C, Alkhidir F, Merlet I, Perault Pochat MC. [Drug-induced dementia: a case/non-case study in the French Pharmacovigilance database]. Therapie 2007; 62: 50711.
  • 4
    Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44: 5138.
  • 5
    Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. [French pharmacovigilance database system: examples of utilisation]. Therapie 1995; 50: 55762.
  • 6
    Lugardon S, Lapeyre-Mestre M, Montastruc JL. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 2004; 60: 6737.
  • 7
    Ewans SJW. Statistics: analysis and presentation of safety data. In: Stephen's Detection of New Adverse Drug Reactions, 5th edn. eds Talbot J, Waller P. Chichester: Wiley, 2004; 30128.
  • 8
    Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL. Drugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2010; 69: 28794.
  • 9
    Beau-Salinas F, Jonville-Bera AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E. Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 2010; 66: 4137.
  • 10
    Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. Br J Clin Pharmacol 1984; 18 (Suppl. 1): 45S49S.
  • 11
    Rudolph U, Mohler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 2006; 6: 1823.
  • 12
    Savic MM, Obradovic DI, Ugresic ND, Bokonjic DR. Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes. Neural Plast 2005; 12: 28998.
  • 13
    Lobo BL, Greene WL. Zolpidem: distinct from triazolam? Ann Pharmacother 1997; 31: 62532.
  • 14
    Declerk A, Bisserbe J. Short-term safety profile of zolpidem: objective measures of cognitive effects. Eur Psychiatry 1997; 12 (Suppl. 1): 1520.
  • 15
    Agnoli A, Manna V, Martucci N. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharmacol Res 1989; 9: 27781.
  • 16
    Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 1990; 5: 17383.
  • 17
    Julou L, Blanchard JC, Dreyfus JF. Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 1985; 23: 6539.
  • 18
    Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162: 22533.
  • 19
    Warot D, Bensimon G, Danjou P, Puech AJ. Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers. Fundam Clin Pharmacol 1987; 1: 14552.
  • 20
    Amado-Boccara I, Gougoulis N, Poirier Littre MF, Galinowski A, Loo H. Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 1995; 19: 47993.
  • 21
    Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 1997; 17 (Suppl. 1): 2S18S.
  • 22
    Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 130522.
  • 23
    Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 51127.
  • 24
    Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59 (Suppl. 4): 514.
  • 25
    Fuller RW. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res 1995; 45: 167204.
  • 26
    Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 (Suppl. 1): 1926.
  • 27
    Stahl SM. [Psychopharmacologie essentielle, 1ère édition française]. Paris: Ed Médecine-Sciences, 1998.
  • 28
    Altman HJ, Nordy DA, Ogren SO. Role of serotonin in memory: facilitation by alaproclate and zimeldine. Psychopharmacology (Berl) 1984; 84: 496502.
  • 29
    Hong E, Meneses A. The activation of serotonergic 5-HT1A presynaptic receptors or an enhancement of 5-HT postsynaptic activity increase learning. Proc West Pharmacol Soc 1995; 38: 856.
  • 30
    Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev 1999; 23: 111125.
  • 31
    Izquierdo I, Medina JH, Izquierdo LA, Barros DM, de Souza MM, Mello e Souza T. Short- and long-term memory are differentially regulated by monoaminergic systems in the rat brain. Neurobiol Learn Mem 1998; 69: 21924.
  • 32
    Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. Arch Gen Psychiatry 1989; 46: 5429.
  • 33
    Mongeau R, Blier P, de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev 1997; 23: 14595.
  • 34
    Vanderwolf CH. Near-total loss of ‘learning’ and ‘memory’ as a result of combined cholinergic and serotonergic blockade in the rat. Behav Brain Res 1987; 23: 4357.
  • 35
    Ögren SO, Stone WS, Altman HJ. Evidence for a functional interaction between serotoninergic and cholinergic mechanisms in memory retrieval. Soc Neurosc Abstract 1985; 256: 11.
  • 36
    Garrigou D, Broekkamp CL, Lloyd KG. Involvement of the amygdala in the effect of antidepressants on the passive avoidance deficit in bulbectomised rats. Psychopharmacology (Berl) 1981; 74: 6670.
  • 37
    Strek KF, Spencer KR, DeNoble VJ. Manipulation of serotonin protects against an hypoxia-induced deficit of a passive avoidance response in rats. Pharmacol Biochem Behav 1989; 33: 2414.
  • 38
    Nowakowska E, Chodera A, Kus K. Anxiolytic and memory improving activity of fluoxetine. Pol J Pharmacol 1996; 48: 25560.
  • 39
    Smith SJ, Kocen RS. A Creutzfeldt-Jakob like syndrome due to lithium toxicity. J Neurol Neurosurg Psychiatry 1988; 51: 1203.
  • 40
    Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990; 51: 3445.
  • 41
    Caer-Frouard M, Weill-Engerer S, Piette F. [Medication and memory: interactions among the elderly]. Presse Med 2006; 35: 916.
  • 42
    Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 38190.
  • 43
    Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36 (Suppl. 2): S4665.
  • 44
    Nichols ME, Meador KJ, Loring DW. Neuropsychological effects of antiepileptic drugs: a current perspective. Clin Neuropharmacol 1993; 16: 47184.
  • 45
    Lamberty Y, Margineanu DG, Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav 2000; 1: 33342.
  • 46
    Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, Steinhoff BJ, Schulze-Bonhage A. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10: 48694.
  • 47
    Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 167883.
  • 48
    Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000; 69: 63641.
  • 49
    Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 4119.
  • 50
    Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 2006; 9: 42431.
  • 51
    O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 2000; 85: 20915.
  • 52
    Marsepoil T, Petithory J, Faucher JM, Ho P, Viriot E, Benaiche F. [Encephalopathy and memory disorders during treatments with mefloquine]. Rev Med Interne 1993; 14: 78891.
  • 53
    Begaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie 1985; 40: 1118.